信达生物的 mazdutide 显示中国成年人的体重显著减轻，计划于今年在中国推出。 Innovent Biologics' mazdutide shows significant weight loss in Chinese adults, set to launch in China this year.

《新英格兰医学杂志》出版的《新英格兰医学杂志》刊登了创新生物学第3阶段关于马兹杜迪德的新肥胖治疗研究,该研究显示,超重或肥胖的中国成年人体重显著下降。 Innovent Biologics' Phase 3 study on mazdutide, a new obesity treatment, showed significant weight loss in Chinese adults with overweight or obesity, published in The New England Journal of Medicine. 该药物比安慰剂更有效地减少体重,今年将在中国推出,用于体重管理和血糖控制。 The drug, which reduces body weight more effectively than a placebo, is set to launch in China this year for weight management and glycemic control. 专家们强调需要将药物疗法与公共卫生政策相结合,以有效解决肥胖问题。 Experts highlight the need for drug therapies to be combined with public health policies to address obesity effectively.